Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
The discovery of immune checkpoint inhibitors (ICIs) has now been universally
acknowledged as a significant breakthrough in tumor therapy after the targeted treatment of …
acknowledged as a significant breakthrough in tumor therapy after the targeted treatment of …
Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy
T Tang, X Huang, G Zhang, Z Hong, X Bai… - Signal transduction and …, 2021 - nature.com
Despite great success in cancer immunotherapy, immune checkpoint-targeting drugs are not
the most popular weapon in the armory of cancer therapy. Accumulating evidence suggests …
the most popular weapon in the armory of cancer therapy. Accumulating evidence suggests …
Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors
R Grosser, L Cherkassky, N Chintala, PS Adusumilli - Cancer cell, 2019 - cell.com
Checkpoint blockade (CPB) therapy can elicit durable clinical responses by reactivating an
exhausted immune response. However, response rates remain limited, likely secondary to a …
exhausted immune response. However, response rates remain limited, likely secondary to a …
[HTML][HTML] Recent strategies for nano-based PTT combined with immunotherapy: from a biomaterial point of view
X Huang, Y Lu, M Guo, S Du, N Han - Theranostics, 2021 - ncbi.nlm.nih.gov
Cancer has been a great threat to humans for decades. Due to the limitations of
monotherapy, combinational therapies such as photothermal therapy (PTT) and …
monotherapy, combinational therapies such as photothermal therapy (PTT) and …
Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations
CR Bell, VS Pelly, A Moeini, SC Chiang… - Nature …, 2022 - nature.com
Cytotoxic therapies, besides directly inducing cancer cell death, can stimulate immune-
dependent tumor growth control or paradoxically accelerate tumor progression. The …
dependent tumor growth control or paradoxically accelerate tumor progression. The …
An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion
JD Klement, AV Paschall, PS Redd… - The Journal of …, 2018 - Am Soc Clin Investig
Despite breakthroughs in immune checkpoint inhibitor (ICI) immunotherapy, not all human
cancers respond to ICI immunotherapy and a large fraction of patients with the responsive …
cancers respond to ICI immunotherapy and a large fraction of patients with the responsive …
Tumor heterogeneity: a great barrier in the age of cancer immunotherapy
Simple Summary Despite great advances in cancer therapy, tumor heterogeneity continues
to be a great barrier for the successful treatment of cancer. It has long been established that …
to be a great barrier for the successful treatment of cancer. It has long been established that …
Regulatory T cells restrain interleukin-2-and Blimp-1-dependent acquisition of cytotoxic function by CD4+ T cells
A Śledzińska, MV de Mucha, K Bergerhoff, A Hotblack… - Immunity, 2020 - cell.com
In addition to helper and regulatory potential, CD4+ T cells also acquire cytotoxic activity
marked by granzyme B (GzmB) expression and the ability to promote rejection of …
marked by granzyme B (GzmB) expression and the ability to promote rejection of …
The nitrogen mustards
The nitrogen mustards are powerful cytotoxic and lymphoablative agents and have been
used for more than 60 years. They are employed in the treatment of cancers, sarcomas, and …
used for more than 60 years. They are employed in the treatment of cancers, sarcomas, and …
Immune checkpoint inhibitor‐based strategies for synergistic cancer therapy
Immune checkpoint blockade therapy (ICBT) targeting checkpoints, such as, cytotoxic T‐
lymphocyte associated protein‐4 (CTLA‐4), programmed death‐1 (PD‐1), or programmed …
lymphocyte associated protein‐4 (CTLA‐4), programmed death‐1 (PD‐1), or programmed …